However, the company stated that its revenue from operations registered a growth of 66.90% to ₹534.70 Crore in Q3FY25.

The revenue increased by 8% YoY to ₹11,995 crores against ₹11,066 crores in Q3 FY24 due to strong demand in the market.

Today, majors across segments including Godfrey Phillips, United Breweries, Senco Gold, Reliance Infra, Hindalco, Healthcare ...

For Ashok Leyland, margin expansion, driven by a better sales mix and pricing power, has boosted investor sentiment. With ...

Anand Rathi is bullish on Ashok Leyland has recommended buy rating on the stock with a target price of Rs 260 in its research ...

The top management has also revealed plans to invest INR 500 crore in Optare PLC, the holding company of Ashok Leyland’s ...

Natco Pharma plans to launch its CTPR products very shortly, which is estimated to have a market size of over ₹2,000 crore in India. Natco Pharma shares surged after the drug maker unveiled the first ...

The Q3FY25 revenue from operations stood at Rs 11,995 crore, an increase of over 8% from Rs 11,066 crore reported in the ...

Ashok Leyland's Ebitda margin expanded 80 basis points (bps) to 12.8 per cent in Q3FY25, up from 12 per cent in Q3FY24, ...